Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
The panel reviews results from the ATTEND and DUO-E trials in advanced endometrial cancer, suggesting pembrolizumab remains the standard for the dMMR patient subset while combinations with PARP inhibitors may improve outcomes in pMMR.
EP: 1.Diagnosing and Staging Patients With Endometrial Cancer
EP: 2.Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 3.Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
EP: 4.The Role of dMMR in the Progression of Endometrial Cancer
EP: 5.Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
EP: 6.The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
Now Viewing
EP: 7.Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
EP: 8.Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
EP: 9.Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
EP: 10.Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 11.Staging and Biomarker Testing For Patients With Cervical Cancer
EP: 12.Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
EP: 13.Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
EP: 14.Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
EP: 15.Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
EP: 16.Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
EP: 17.Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
Related Videos
Related Content
